Certara
About Certara
Certara is a global leader in model-informed drug development (MIDD), providing biosimulation software and technology-enabled services to pharmaceutical, biotechnology, and regulatory organizations. The company operates at the intersection of life sciences, data science, and regulatory science, aiming to transform traditional drug discovery and development to accelerate medicines to patients. Their offerings are used to simulate how drugs behave in the human body, optimize clinical trial design, and support regulatory submissions. Certara’s approach helps clients reduce the need for extensive clinical trials, accelerate regulatory approval, and increase patient access to medicines.
For physicians, Certara’s technologies and services translate into more efficient and effective drug development, ultimately leading to new and improved therapies reaching patients faster. Their biosimulation software and AI-enabled platforms, such as Certara.AI and Certara IQ, empower researchers to make data-driven decisions throughout the drug development lifecycle, from discovery and preclinical stages to clinical development, regulatory affairs, and market access. This includes optimizing trial designs, predicting drug outcomes, and generating robust evidence for regulatory submissions, which can be particularly valuable in complex therapeutic areas like oncology, rare diseases, and cell and gene therapy.
Certara also offers consulting services, providing therapeutic area-specific insights and strategic guidance to bridge knowledge gaps, optimize design parameters, and de-risk decisions in drug development. Their expertise in model-informed drug development is increasingly encouraged by regulatory agencies to improve efficiency and reduce development risk, with Certara’s tools frequently used in submissions to the U.S. Food and Drug Administration (FDA) and other global regulators.
Focus Areas
Business Intelligence
| Key Investors | Arsenal Capital Partners, BlackRock, Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, Deerfield Management Company, L.p. (series C), Jefferies Financial Group Inc., Vanguard Portfolio Management Llc, Vanguard Capital Management Llc, Wasatch Advisors Inc, ArrowMark Colorado Holdings LLC, Citadel Advisors Llc |
| Partnerships | Altasciences, Merck, NVIDIA |
| Acquisitions | Tripos (2007), Pharsight (2008), Simcyp (2012), Synchrogenix (2014), ClinGenuity (2015), XenologiQ (2015), d3 Medicine (2016), BaseCase (2017), Pinnacle 21 (2021), Integrated Nonclinical Development Solutions (INDS) (2022), Formedix (2022), Vyasa (2023), ChemAxon (2024), Applied Biomath (2024) |
| Technology | Certara.AI (AI platform for life sciences), Simcyp Simulator (PBPK modeling), Phoenix Platform (PK/PD analysis), D360 (scientific informatics), Pinnacle 21 (clinical data validation), GlobalSubmit (eCTD software), CoAuthor (GPT-powered regulatory writing platform), Certara IQ (AI-enabled QSP modeling software) |
| FDA Clearances | Certara's biosimulation technology supported nearly 90% of FDA novel drug approvals in 2020, and 90% or more of all novel drug approvals by the FDA from 2014 through 2025. cleared products (estimated) |
What Physicians Need to Know
For physicians, Certara's expertise translates to a faster and more efficient drug development process, potentially leading to earlier access to new and more effective therapies. Their biosimulation and PBPK modeling capabilities, particularly with the Simcypu00ae Simulator, mean that drug dosing and potential drug interactions are more thoroughly understood and predicted, even for special populations like pediatrics or those with organ impairment, reducing risks and optimizing treatment strategies. The use of AI in drug discovery and clinical trial simulation can lead to more targeted and successful trials, ultimately bringing safer and more efficacious drugs to patients. Furthermore, their focus on regulatory science and clinical data validation ensures that the data supporting new drug approvals is robust and reliable, contributing to greater confidence in prescribing decisions. Certara's market access solutions also aim to ensure that valuable therapies are accessible to patients.
Certara's technology stack includes proprietary software like the Simcypu00ae Simulator, D360u2122 Scientific Informatics Platform, Pinnacle 21u00ae Enterprise, Trial Simulator, Certara IQ (AI-enabled QSP modeling software), and CoAuthoru2122 GenAI software for medical writing. They integrate their modeling platforms with research data systems and analytical tools. Certara is also partnering with NVIDIA to advance its integrated AI platform, incorporating the BioNeMo Agent Toolkit. Their CoAuthoru2122 software seamlessly integrates with Veeva RIM to simplify digital data flows and accelerate regulatory submissions. They also partner with companies like TetraScience to enhance drug discovery and development through data-driven insights by leveraging Tetra Data within D360.
What the Web Says
Certara is a global leader in biosimulation software and technology, offering a comprehensive suite of tools for drug discovery and development. The company receives generally positive reviews for its products, which are widely adopted by pharmaceutical companies and regulatory agencies. Employer reviews indicate a mixed sentiment, with many praising work-life balance and career development opportunities, but some expressing concerns about upper management and integration challenges due to acquisitions.
Overall: MixedStrengths
- Widely adopted and trusted biosimulation software by pharmaceutical companies and regulatory agencies.
- Products like Phoenix WinNonlin and Simcyp Simulator are considered industry standards.
- Strong focus on model-informed drug development (MIDD) and AI integration for accelerating R&D.
- Good work-life balance and time off flexibility for employees.
- Opportunities for career development and annual raises based on performance.
- Supportive environment and collaborative culture among colleagues.
Limitations
- Concerns about upper management's expectations and involvement in day-to-day work.
- Perceived lack of loyalty from management to long-term employees.
- Challenges with integrating acquired companies and their employees.
- Limited growth ladder and lack of clear banding documents in HR and other support functions.
- Some employees feel managers use team members as 'pawns'.
- Infrastructure limitations and scalability issues noted in some product reviews (though this might be referring to a different company named Certa).
Based on reviews from: Great Place To Work, G2, Indeed.com, Certara Careers, IntuitionLabs, Reddit, Certara.AI, Pharma Focus Asia, ZipRecruiter, Sick Economics
Last updated: 2026-07-10
Videos
News, demos, and interviews about Certara.
Videos load interactively. If none appear, search YouTube for Certara →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Certara.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]